Evolent Health, Inc Class A Common Stock
Here’s whether Evolent Health, Inc Class A Common Stock (EVH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.74% over 10 days); RSI 49 — healthy momentum range; 3-month momentum positive (+54.3%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -46.3%. Currently 67.3% off its 52-week high. Score: +1/7.
EVH is trading below its 200-day MA ($5.10) — a key warning sign the longer-term trend is under pressure. An RSI of 48.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -46.3% compares to +27.9% for SPY (trailed the market by 74.2%). The current 67.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.